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LETTERS TO THE EDITOR
Cytarabine preferentially induces mutation at specific
sequences in the genome which are identifiable in relapsed
acute myeloid leukaemia
Leukemia (2015) 29, 491–494; doi:10.1038/leu.2014.284
Cytarabine (1-β-D-arabinofuranosylcytosine; Ara-C) is an effective
remission induction treatment for acute myeloid leukemia
(AML).1,2 However, the majority of patients relapse within
3 years, often with aggressive AML2 characterised by the gain of
novel base substitution mutations in genes including IDH2 and
TET2.3,4 Chemotherapy used to treat AML is predicted to
induce mutations detectable in relapsed disease, although direct
evidence for this is lacking. The cytotoxicity of Ara-C is mediated in
part by incorporation into replicating DNA leading to inhibition
of chain extension. However, even at concentrations that induce
significant cell death, arabinofuranosylcytosine triphosphate,
the reactive metabolite of Ara-C, is primarily incorporated into
DNA at internucleotide positions,5,6 suggesting that this
nucleoside analogue is likely mutagenic and could contribute to
the aetiology of novel somatic mutations acquired during AML
relapse.
To assess the mutagenicity of Ara-C, mutation frequency (Mf)
was determined in TK6 cells in vitro at two widely used reporter
genes, thymidine kinase (TK) and hypoxanthine-guanine phosphor-
ibosyltransferase (HPRT). The procedure for performing in vitro
quantitative mutation assays was developed by Liber and Thilly7
and involves treatment of cells under defined conditions, followed
by incubation in non-selective medium for a time sufficient to
allow phenotypic expression of the chosen genetic marker. Cells
were then plated in the presence of selective agent to determine
the number of mutant cells able to form colonies and in the
absence of selective agent in order to determine the intrinsic
cloning efficiency of the cells. Mf was calculated following
adjustment for cloning efficiency and is described in detail in
Supplementary Methods.
A significant Ara-C dose-dependant increase in Mf was
observed in surviving cells at both loci, although Ara-C induced
fewer mutations in surviving cells compared to the powerful
mutagen MNU at equitoxic doses (Figure 1a). Ara-C-induced Mf
was next determined in isogenic cells deficient in MSH2,8 a
component of DNA mismatch repair (MMR) that when lost confers
sensitivity to mutagenesis by agents that induce base:base
mispairs.9 MSH2-deficient cells were more susceptible to Ara-C-
induced mutation than their MMR-proficient counterparts (Figures
1a and b and Supplementary Figure S1), demonstrating a
significant influence of both Ara-C dose and MMR status on Mf
(Po0.001). These data confirm the mutagenicity of this anti-
leukaemic cytosine analogue and suggest it to be a base
substitution mutagen.
In order to determine whether Ara-C preferentially induces
mutation at specific sequences in the genome, a mutation
spectrum at the HPRT locus was generated. Cells were exposed
to 30 nM Ara-C (or vehicle) for 16 hours and mutant colonies
were generated as described by Liber and Thilly.7 A single
mutant colony from each treated cell population was expanded
in standard growth medium supplemented with 2 μg/ml
6-thioguanine and RNA/DNA extracted for subsequent characterisation
(Supplementary Methods). This procedure was performed
up to 150 times for Ara-C and vehicle, ensuring full independence
of mutant colonies. The mutation spectra from Ara-C-treated
and vehicle-treated cells were significantly different (P= 0.002),
with the proportion of base substitutions higher in Ara-C-treated
cells (27 vs 19%; Figure 1c and Supplementary Table S1). Strikingly,
7 of 27 (25.9%) base substitution mutations from Ara-C-treated
clones affected the central G:C base-pair in 5′TpGpA3′/5′TpCpA3′
sequences (Figure 1d and Supplementary Table S2), including
6 single base substitutions and 1 tandem base substitution
at five different sites in the HPRT gene. Using Monte–Carlo
simulation, the probability of 7 or more mutations at the
central position of any one of the 32 possible trinucleotide
sequences occurring by chance was calculated as 4.7 × 10−4.
Mutation at the central position of 5′TpGpA3′/5′TpCpA3′ sequences
was observed only once in vehicle-treated control cells (1/25,
4.0%) and none of the other 31 possible trinucleotide sequences
were represented more than twice in the Ara-C mutation
spectrum (Figure 1d).
Ara-C induces significant perturbation of the DNA helix which
could cause mutation at neighbouring base positions.10 Consis-
tent with this phenomenon, five additional base substitution
mutations in Ara-C-treated cells were identified at non-central
positions in 5′TpGpA3′/5′TpCpA3′ sequences, but none were
observed in vehicle-treated control cells (Figure 1e and
Supplementary Table S2). In total, 12 of 27 (44.4%) base
substitution mutations in Ara-C-treated cells occurred in
5′TpGpA3′/5′TpCpA3′ sequences, compared to only 1 of 25 (4.0%)
in control cells. Using Monte–Carlo simulation, the probability of
12 or more mutations at any of the three base positions in any one
of the 32 possible trinucleotide sequences occurring by chance
was calculated as 2.6 × 10− 4. These data demonstrate that Ara-C
preferentially induces mutation in 5′TpGpA3′/5′TpCpA3′ sequences,
and particularly at the central G:C position consistent with its
function as a cytosine analogue.
We next looked for mutation at 5′TpGpA3′/5′TpCpA3′ sequences
in AML patients treated with Ara-C. Whole genome sequencing
data from eight AML patients3 were analysed as described in
Supplementary Methods. A total of 3587 and 452 somatic
mutations were analysed from presentation and relapse disease,
respectively. The frequency of mutation at the G:C position in
5′TpGpA3′/5′TpCpA3′ sequences was significantly higher in
relapsed AML (22/452, 4.9%) compared to chemotherapy-naive
presentation AML (111/3587, 3.1%; odds ratio (OR) 2.2, 95%
confidence interval (CI) 1.4–3.6; P= 0.003; Table 1 and
Supplementary Table S3), consistent with an Ara-C-induced
mutation signature. It should be noted that Ara-C makes a
relatively small contribution to relapse mutation load and that
other mechanisms might be more important for driving the
acquisition of novel mutations in relapsed samples. Specifically, of
the 452 novel base substitution mutations seen at relapse, the
OPEN
Accepted article preview online 24 September 2014; advance online publication, 17 October 2014
Leukemia (2015) 29, 491–514
© 2015 Macmillan Publishers Limited All rights reserved 0887-6924/15
www.nature.com/leu
excess mutations at the G:C position in 5′TpGpA3′/5′TpCpA3′
sequences, and potentially attributable to Ara-C, constitute less
than 2% of all novel relapse-specific mutations.
In order to exclude the possibility that the specific acquisition of
mutation at 5′TpGpA3′/5′TpCpA3′ sequences is intrinsic to disease
progression, sequencing data were also analysed from
three patients at diagnosis of myelodysplastic syndrome
(MDS) who subsequently progressed to AML.11 These patients
had not received any therapy other than supportive care
for MDS (Supplementary Methods). The frequency of G:C
mutations at 5′TpGpA3′/5′TpCpA3′ sequences was similar in
MDS (34/1122; 3.0%) and presentation AML (13/428, 3.0%; OR
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1.1, 95% CI 0.5–2.3, P = 0.882; Supplementary Table S4), further
implicating Ara-C as the cause of mutation at these sites in
relapse AML.
It will also be important to establish the contribution of other
remission induction agents to mutation in relapsing AML.
In addition to 5′TpGpA3′/5′TpCpA3′, the frequency of mutation
Table 1. Frequency of somatic mutation at the central base of trinucleotide sequences in AML patients at presentation (before Ara-C treatment) and
relapse (post-Ara-C treatment)
Trinucleotide sequencea n (%)b ORc 95% CIc P-valuec
Pres Rel
5′ApApA3′/5′TpTpT3′ 97 (2.7) 12 (2.7) 0.89 0.47–1.66 0.709
5′ApApC3′/5′GpTpT3′ 55 (1.5) 6 (1.3) 0.81 0.34–1.94 0.636
5′ApApG3′/5′CpTpT3′ 79 (2.2) 9 (2.0) 0.9 0.44–1.84 0.766
5′ApApT3′/5′ApTpT3′ 117 (3.3) 15 (3.3) 0.92 0.53–1.62 0.78
5′ApCpA3′/5′TpGpT3′ 209 (5.8) 28 (6.2) 0.97 0.64–1.47 0.876
5′ApCpC3′/5′GpGpT3′ 118 (3.3) 8 (1.8) 0.51 0.25–1.07 0.074
5′ApCpG3′/5′CpGpT3′ 408 (11.4) 39 (8.6) 0.9 0.63–1.29 0.567
5′ApCpT3′/5′ApGpT3′ 137 (3.8) 19 (4.2) 0.94 0.57–1.56 0.816
5′CpApA3′/5′TpTpG3′ 39 (1.1) 4 (0.9) 0.7 0.24–1.99 0.499
5′CpApC3′/5′GpTpG3′ 32 (0.9) 5 (1.1) 1.33 0.50–3.55 0.567
5′CpApG3′/5′CpTpG3′ 74 (2.1) 9 (2.0) 0.94 0.45–1.94 0.861
5′CpApT3′/5′ApTpG3′ 95 (2.6) 10 (2.2) 0.65 0.33–1.29 0.217
5′CpCpA3′/5′TpGpG3′ 115 (3.2) 14 (3.1) 0.86 0.79–1.53 0.615
5′CpCpC3′/5′GpGpG3′ 98 (2.7) 10 (2.2) 0.68 0.35–1.34 0.271
5′CpCpG3′/5′CpGpG3′ 221 (6.2) 28 (6.2) 1.34 0.87–2.05 0.184
5′CpCpT3′/5′ApGpG3′ 162 (4.5) 16 (3.5) 0.65 0.38–1.10 0.11
5′GpApA3′/5′TpTpC3′ 53 (1.5) 7 (1.5) 0.82 0.36–1.85 0.633
5′GpApC3′/5′GpTpC3′ 38 (1.1) 3 (0.7) 0.56 0.17–1.83 0.334
5′GpApG3′/5′CpTpC3′ 43 (1.2) 8 (1.8) 1.34 0.61–2.96 0.469
5′GpApT3′/5′ApTpC3′ 53 (1.5) 8 (1.8) 1.33 0.60–2.91 0.482
5′GpCpA3′/5′TpGpC3′ 112 (3.1) 14 (3.1) 0.92 0.51–1.64 0.773
5′GpCpC3′/5′GpGpC3′ 81 (2.3) 16 (3.5) 1.43 0.81–2.53 0.221
5′GpCpG3′/5′CpGpC3′ 233 (6.5) 19 (4.2) 0.8 0.49–1.32 0.389
5′GpCpT3′/5′ApGpC3′ 144 (4.0) 10 (2.2) 0.5 0.26–0.96 0.037
5′TpApA3′/5′TpTpA3′ 60 (1.7) 18 (4.0) 1.9 1.08–3.33 0.025
5′TpApC3′/5′GpTpA3′ 40 (1.1) 5 (1.1) 0.99 0.38–2.57 0.979
5′TpApG3′/5′CpTpA3′ 39 (1.1) 17 (3.8) 3.43 1.86–6.32 o0.001
5′TpApT3′/5′ApTpA3′ 90 (2.5) 8 (1.8) 0.58 0.28–1.21 0.146
5′TpCpA3′/5′TpGpA3′ 111 (3.1) 22 (4.9) 2.17 1.30–3.61 0.003
5′TpCpC3′/5′GpGpA3′ 105 (2.9) 11 (2.4) 0.88 0.46–1.70 0.713
5′TpCpG3′/5′CpGpA3′ 175 (4.9) 13 (2.9) 0.7 0.38–1.26 0.23
5′TpCpT3′/5′ApGpA3′ 154 (4.3) 41 (9.1) 2.55 1.73–3.76 o0.001
Total 3587 (100) 452 (100)
Abbreviations: CI, confidence interval; n, total number of mutants analysed; Pres, presentation; Rel, relapse; OR, odds ratio. The Ara-C target sequence
(5′TpCpA3′/5′TpGpA3′) is highlighted in bold. For this triplet sequence, binomial logistic regression analysis of data from eight patients with exclusion of a
single case at each iteration, retained significance in all instances (Po0.050), demonstrating that the association was not solely due to any one patient.
aMutations at the central base position in any given trinucleotide sequence (the mutated base and 1 base 5′ and 3′ of the mutated base) were grouped with
mutations in their complement sequence. bData is presented as the number of base substitution mutations at the central position of each trinucleotide from a
total of 3587 at presentation and 452 at relapse from a total of 8 patients. Numbers in parentheses indicate mutation at each trinucleotide as a percentage of
the total in the pooled dataset. cOR, 95% CI and associated P-values were calculated using binomial regression analysis of data from the 8 individual patients
comprising the dataset (see Supplementary Table S3).
Figure 1. Mutagenicity of Ara-C in vitro. Mf at TK and HPRT loci was assessed in DNA MMR-proficient TK6 lymphoblastoid cells (a) or isogenic
MMR-deficient MSH2i cells (b) following either 16 h exposure to Ara-C (blue squares) or 4 h exposure to MNU (orange triangles). Data
represents the mean and standard error of three independently treated cell populations and is presented as Mf observed in control vehicle-
treated cells (0% cytotoxicity) and at drug doses causing upto 95% cytotoxicity (see Supplementary Figure. 1). Exponential curves are
displayed for each dataset. The associated R2 values represent the square of the Pearson product moment correlation coefficient, indicating
the ‘goodness of fit’ of the data. (c) spectrum of independent mutations observed at the HPRT locus following 16 h exposure to 30 nM Ara-C
(inducing ~ 95% cytotoxicity) or vehicle control in B-lymphoblastoid TK6 cells. Coloured sections represent different structural classes of
mutation observed. Numbers in parentheses indicate the proportion of mutants in each class. Total number of mutants analysed (n) is shown
above the bars. P-value was calculated by Fisher’s exact test comparing the distribution of structural mutations (large deletions, small
deletions, base substitutions and partial gene duplications) derived from Ara-C treated cells with those derived from vehicle-treated cells.
(d and e) the sequence context of HPRT base substitution mutations from control vehicle-treated and Ara-C-treated cells (see Supplementary
Table S2). Heatmaps display the number of base substitution mutations at the central position (d) or any position (e) of all possible
trinucleotide sequences in vehicle- (top) or Ara-C-treated (bottom) cells. It was not possible to discern whether base substitution mutation was
initiated due to a mis-insertion on the plus or minus strand. As such, for the purposes of this analysis, mutations in any given trinucleotide
sequence (the mutated base and 1 base 5′ and 3′ of the mutated base) were grouped with mutations in their complement sequence.
For vehicle-treated cells, the sequence context of 25 single base substitutions was analysed. For Ara-C treated cells, the sequence context
of 25 single base substitutions and 1 tandem base substitution (scored at both positions) were analysed.
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at three other trinucleotides was also significantly higher in
relapsed AML compared to presentation disease (Table 1),
suggesting the presence of mutation signatures from other
chemotherapy agents.
In summary, these data demonstrate that Ara-C preferentially
induces mutation at 5′TpGpA3′/5′TpCpA3′ sequences which are
significantly elevated in relapse disease after exposure to Ara-C-
containing regimens. Given the relationship between Ara-C dose
and mutagenicity reported here, a consideration of chemotherapy-
induced mutagenicity could be important when developing
strategies for treating AML that maximise the likelihood of remission
whilst minimising the risk of mutation in surviving cells which could
contribute to evolution of relapse disease.
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MARIMO cells harbor a CALR mutation but are not
dependent on JAK2/STAT5 signaling
Leukemia (2015) 29, 494–497; doi:10.1038/leu.2014.285
Mutations in calreticulin (CALR) were recently described to be present in
the majority of patients with a JAK2-unmutated myeloproliferative
neoplasm (MPN).1,2 This discovery has had rapid clinical impact, and
testing for CALR has been embedded in national and international
diagnostic guidelines.3–5 However, a human MPN-derived cell line
harboring a CALR mutation has not been reported and the
mechanisms by which mutated-CALR results in an MPN remain unclear.
To begin to investigate the pathogenetic consequences of mutant
CALR, we searched for patient-derived cell lines harboring CALR
mutations. None were identified by exome sequencing of 1015 cell
lines, including 37 derived from hematopoietic neoplasms.1 We
therefore looked for cell lines derived from patients with leukemic
transformation of a preceding MPN. Given that CALR and JAK2
mutations are almost completely mutually exclusive,1,2,6 we focused
on four such lines known to lack a JAK2 mutation (MONO-MAC-6,
MARIMO, GDM-1 and ELF-153), and also tested a further 52 other
predominantly myeloid cell lines (Supplementary Table 1).
Mutation screening was done by Sanger sequencing as previously
described,1 and details of other methods are in the Supplementary
Information.
The only cell line found to harbor a CALR mutation was
MARIMO, originally derived from a 68-year-old female with
AML-M2, and an antecedent history of ET.7 MARIMO is negative
for JAK2V617F and MPL exon 10 mutations (data not shown)
and carries a heterozygous 61-basepair (bp) deletion in CALR
exon 9 (c.1099_1159del; L367fs*43), which, like all other
reported CALR mutations, results in a +1- bp shift in the reading
frame and thus generates a novel C terminus (Figure 1a). In
patients, the commonest two CALR mutations, accounting for
85% of cases, are a 52-bp deletion (type 1; c.1099_1150del;
L367fs*46) and a 5-bp insertion (type 2; c.1154_1155_ins;
Accepted article preview online 24 September 2014; advance online publication, 17 October 2014
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